Clinical Trials
Custom Pages

CGX1321 Trials

CGX1321, a novel WNT pathway inhibitor of Porcupine, represents a potential treatment for cancer and other WNT-driven diseases such as fibrosis. CGX1321 has completed the phase 1 clinical studies in the United States and China, and is undergoing efficacy dose-expansion and phase 1b combination with Keytruda clinical trials. To enroll in the following studies:

Get In Touch with Curegenix

    Curegenix is a clinical-stage company with operations in the San Francisco Bay Area and Guangzhou China. We focus on the discovery and development of novel drugs.

    Get In Touch with Curegenix

      Copyright 2021 Curegenix Corporation | All Rights Reserved